Individualized administration of Venetoclax based on PK/PD in children with refractory/relapsed acute leukemia

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057796

Enrollment

Unknown

Registered

2022-03-17

Start date

2022-03-18

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric acute leukemia

Interventions

experimental group:Venetoclax-based regimen

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Aged 0-18 years; 2. Meet the diagnostic criteria of refractory/relapsed acute leukemia; 3. Venetoclax treatment; 4. Patients with complete clinical evaluation data; 5. Patients or family members sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who did not monitor the blood concentration of Venetoclax during treatment; 2. Children and their guardians cannot understand or do not follow the study protocol.

Design outcomes

Primary

Measure	Time frame
Plasma drug concentration of venetoclax;Hematologic complete remission;	—

Secondary

Measure	Time frame
Minimal residual disease;Side effect of chemotherapy;Event free survival;	—

Countries

China

Contacts

Public ContactZheng Huyong

Beijing Children's Hospital, Capital Medical University

zhenghuyong@bch.com.cn+86 10 59617621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026